vs
Apellis Pharmaceuticals, Inc.（APLS）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Purple Innovation, Inc.的1.4倍（$199.9M vs $140.7M），Purple Innovation, Inc.净利率更高（-2.3% vs -29.5%，领先27.2%），Purple Innovation, Inc.同比增速更快（9.1% vs -5.9%），Purple Innovation, Inc.自由现金流更多（$-7.8M vs $-14.3M），过去两年Purple Innovation, Inc.的营收复合增速更高（8.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
APLS vs PRPL — 直观对比
营收规模更大
APLS
是对方的1.4倍
$140.7M
营收增速更快
PRPL
高出15.0%
-5.9%
净利率更高
PRPL
高出27.2%
-29.5%
自由现金流更多
PRPL
多$6.5M
$-14.3M
两年增速更快
PRPL
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $140.7M |
| 净利润 | $-59.0M | $-3.2M |
| 毛利率 | — | 41.9% |
| 营业利润率 | -25.6% | -1.6% |
| 净利率 | -29.5% | -2.3% |
| 营收同比 | -5.9% | 9.1% |
| 净利润同比 | -62.2% | 62.1% |
| 每股收益（稀释后） | $-0.40 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPRPL
| Q4 25 | $199.9M | $140.7M | ||
| Q3 25 | $458.6M | $118.8M | ||
| Q2 25 | $178.5M | $105.1M | ||
| Q1 25 | $166.8M | $104.2M | ||
| Q4 24 | $212.5M | $129.0M | ||
| Q3 24 | $196.8M | $118.6M | ||
| Q2 24 | $199.7M | $120.3M | ||
| Q1 24 | $172.3M | $120.0M |
净利润APLSPRPL
| Q4 25 | $-59.0M | $-3.2M | ||
| Q3 25 | $215.7M | $-11.7M | ||
| Q2 25 | $-42.2M | $-17.3M | ||
| Q1 25 | $-92.2M | $-19.1M | ||
| Q4 24 | $-36.4M | $-8.5M | ||
| Q3 24 | $-57.4M | $-39.2M | ||
| Q2 24 | $-37.7M | $27.0K | ||
| Q1 24 | $-66.4M | $-50.2M |
毛利率APLSPRPL
| Q4 25 | — | 41.9% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 35.9% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 34.8% |
营业利润率APLSPRPL
| Q4 25 | -25.6% | -1.6% | ||
| Q3 25 | 48.7% | -10.2% | ||
| Q2 25 | -18.6% | -13.5% | ||
| Q1 25 | -50.0% | -13.9% | ||
| Q4 24 | -12.3% | -6.0% | ||
| Q3 24 | -24.0% | -39.5% | ||
| Q2 24 | -14.7% | -12.1% | ||
| Q1 24 | -36.0% | -19.3% |
净利率APLSPRPL
| Q4 25 | -29.5% | -2.3% | ||
| Q3 25 | 47.0% | -9.9% | ||
| Q2 25 | -23.6% | -16.5% | ||
| Q1 25 | -55.3% | -18.4% | ||
| Q4 24 | -17.1% | -6.6% | ||
| Q3 24 | -29.2% | -33.1% | ||
| Q2 24 | -18.9% | 0.0% | ||
| Q1 24 | -38.5% | -41.8% |
每股收益（稀释后）APLSPRPL
| Q4 25 | $-0.40 | $0.03 | ||
| Q3 25 | $1.67 | $0.11 | ||
| Q2 25 | $-0.33 | $0.16 | ||
| Q1 25 | $-0.74 | $0.18 | ||
| Q4 24 | $-0.30 | $0.08 | ||
| Q3 24 | $-0.46 | $0.36 | ||
| Q2 24 | $-0.30 | $0.00 | ||
| Q1 24 | $-0.54 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | $370.1M | $-29.7M |
| 总资产 | $1.1B | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPRPL
| Q4 25 | $466.2M | $24.3M | ||
| Q3 25 | $479.2M | $32.4M | ||
| Q2 25 | $370.0M | $34.2M | ||
| Q1 25 | $358.4M | $21.6M | ||
| Q4 24 | $411.3M | $29.0M | ||
| Q3 24 | $396.9M | $23.4M | ||
| Q2 24 | $360.1M | $23.4M | ||
| Q1 24 | $325.9M | $34.5M |
总债务APLSPRPL
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSPRPL
| Q4 25 | $370.1M | $-29.7M | ||
| Q3 25 | $401.2M | $-26.9M | ||
| Q2 25 | $156.3M | $-15.6M | ||
| Q1 25 | $164.2M | $1.3M | ||
| Q4 24 | $228.5M | $20.2M | ||
| Q3 24 | $237.1M | $28.0M | ||
| Q2 24 | $264.3M | $66.4M | ||
| Q1 24 | $266.7M | $65.5M |
总资产APLSPRPL
| Q4 25 | $1.1B | $296.3M | ||
| Q3 25 | $1.1B | $302.1M | ||
| Q2 25 | $821.4M | $303.8M | ||
| Q1 25 | $807.3M | $293.8M | ||
| Q4 24 | $885.1M | $307.8M | ||
| Q3 24 | $901.9M | $309.3M | ||
| Q2 24 | $904.5M | $362.1M | ||
| Q1 24 | $831.9M | $382.1M |
负债/权益比APLSPRPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-7.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -5.5% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-41.9M |
8季度趋势，按日历期对齐
经营现金流APLSPRPL
| Q4 25 | $-14.2M | $-5.8M | ||
| Q3 25 | $108.5M | $-968.0K | ||
| Q2 25 | $4.4M | $-4.0M | ||
| Q1 25 | $-53.4M | $-23.1M | ||
| Q4 24 | $19.4M | $6.8M | ||
| Q3 24 | $34.1M | $1.1M | ||
| Q2 24 | $-8.3M | $-8.9M | ||
| Q1 24 | $-133.0M | $-16.8M |
自由现金流APLSPRPL
| Q4 25 | $-14.3M | $-7.8M | ||
| Q3 25 | $108.3M | $-1.8M | ||
| Q2 25 | $4.4M | $-7.0M | ||
| Q1 25 | $-53.4M | $-25.3M | ||
| Q4 24 | $19.3M | $5.7M | ||
| Q3 24 | — | $101.0K | ||
| Q2 24 | $-8.4M | $-11.0M | ||
| Q1 24 | $-133.3M | $-19.9M |
自由现金流率APLSPRPL
| Q4 25 | -7.1% | -5.5% | ||
| Q3 25 | 23.6% | -1.5% | ||
| Q2 25 | 2.5% | -6.6% | ||
| Q1 25 | -32.0% | -24.3% | ||
| Q4 24 | 9.1% | 4.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | -4.2% | -9.2% | ||
| Q1 24 | -77.3% | -16.5% |
资本支出强度APLSPRPL
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 1.7% | ||
| Q1 24 | 0.2% | 2.5% |
现金转化率APLSPRPL
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
